What is NDC 70436-114?

70436-114 is the product NDC for Cisatracurium besylate, Cisatracurium besylate 10 mg/mL injection, listed with the FDA by Slate Run Pharmaceuticals, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Slate Run Pharmaceuticals, LLC, NDC labeler code 70436. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Cisatracurium besylate?

34 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Cisatracurium besylate NDC 70436-114

NDC codes

FDA NDC Directory

Product NDC (as listed)70436-114Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70436-0114Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70436-114-82	7043601148270436011482	10 VIAL, SINGLE-DOSE in 1 CARTON (70436-114-82) / 20 mL in 1 VIAL, SINGLE-DOSEMarketed from Sep 2, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cisatracurium besylate
Generic name (nonproprietary): cisatracurium besylate
Active ingredients: Cisatracurium besylate — 10 mg/mL
Dosage form: Injection
Route: Intravenous
Labeler: Slate Run Pharmaceuticals, LLCNDC labeler code 70436
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216539
Marketing start: Sep 2, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Neuromuscular Nondepolarizing Blockade (Physiologic effect)
Identifiers: Product ID 70436-114_20cd9789-700a-5fa0-e063-6394a90a5d0dSPL ID 20cd9789-700a-5fa0-e063-6394a90a5d0dSPL set ID 49185e78-d244-4426-90ef-ad109824eddbRxCUI 199212, 1730194UNII 80YS8O1MBS
Pharmacologic class: Nondepolarizing Neuromuscular Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470436011482 followed by a unit qualifier and the quantity

Package 70436-0114-82. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 29, 2024.

Indications (excerpt from the label)

Cisatracurium Besylate Injection is indicated: as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older Limitations of Use Cisatracurium Besylate Injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. Cisatracurium Besylate Injection is a nondepolarizing neuromuscular blocker indicated: as an adjunct to general anesthe…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70436-114

What is NDC 70436-114?: 70436-114 is the product NDC for Cisatracurium besylate, Cisatracurium besylate 10 mg/mL injection, listed with the FDA by Slate Run Pharmaceuticals, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Cisatracurium besylate.
What is the active ingredient?: Cisatracurium besylate.
Who is the labeler?: Slate Run Pharmaceuticals, LLC, NDC labeler code 70436. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Cisatracurium besylate?: 34 other product NDCs are listed under this name. See all Cisatracurium besylate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Cisatracurium besylate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Cisatracurium Besylate	Cisatracurium besylate 10 mg/mL	Injection, SolutionIntravenous	Avenacy, LLC	83634-655	83634-0655-20
Cisatracurium Besylate	Cisatracurium besylate 10 mg/mL	InjectionIntravenous	Camber Pharmaceuticals Inc.	31722-312	31722-0312-10
Cisatracurium Besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Camber Pharmaceuticals Inc.	31722-313	31722-0313-10
Cisatracurium Besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Camber Pharmaceuticals Inc.	31722-314	31722-0314-10
Cisatracurium besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-486	68083-0486-01
Cisatracurium besylate	Cisatracurium besylate 10 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-487	68083-0487-01
Cisatracurium besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-488	68083-0488-01
Cisatracurium Besylate	Cisatracurium besylate 10 mg/mL	InjectionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9160	00143-9160-10
Cisatracurium Besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9397	00143-9397-10
Cisatracurium besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Caplin Steriles Limited	65145-135	65145-0135-0165145-0135-10

All 35 Cisatracurium besylate NDCs

Other NDCs under ANDA 216539

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216539
Product	Strength	Form · route	Labeler	Product NDC
Cisatracurium besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Slate Run Pharmaceuticals, LLC	70436-112
Cisatracurium Besylate	Cisatracurium besylate 10 mg/mL	Injection, SolutionIntravenous	Avenacy, LLC	83634-655